ALINS Stock Overview
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.38|
|52 Week High||€0.92|
|52 Week Low||€0.26|
|1 Month Change||-12.65%|
|3 Month Change||-19.45%|
|1 Year Change||-59.03%|
|3 Year Change||62.99%|
|5 Year Change||-37.25%|
|Change since IPO||-94.77%|
Recent News & Updates
Does Intrasense (EPA:ALINS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|ALINS||FR Healthcare Services||FR Market|
Return vs Industry: ALINS underperformed the French Healthcare Services industry which returned -12% over the past year.
Return vs Market: ALINS underperformed the French Market which returned -5.4% over the past year.
|ALINS Average Weekly Movement||12.9%|
|Healthcare Services Industry Average Movement||7.5%|
|Market Average Movement||6.1%|
|10% most volatile stocks in FR Market||10.4%|
|10% least volatile stocks in FR Market||3.6%|
Stable Share Price: ALINS is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ALINS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams.
Intrasense Fundamentals Summary
|ALINS fundamental statistics|
Is ALINS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALINS income statement (TTM)|
|Cost of Revenue||€668.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.038|
|Net Profit Margin||-28.74%|
How did ALINS perform over the long term?See historical performance and comparison
Is Intrasense undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALINS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALINS's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALINS is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.
PE vs Market: ALINS is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALINS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALINS is good value based on its PB Ratio (2.4x) compared to the FR Healthcare Services industry average (2.6x).
How is Intrasense forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Intrasense has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Intrasense performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALINS is currently unprofitable.
Growing Profit Margin: ALINS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALINS is unprofitable, but has reduced losses over the past 5 years at a rate of 15.8% per year.
Accelerating Growth: Unable to compare ALINS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALINS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3%).
Return on Equity
High ROE: ALINS has a negative Return on Equity (-24.12%), as it is currently unprofitable.
How is Intrasense's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALINS's short term assets (€6.7M) exceed its short term liabilities (€2.1M).
Long Term Liabilities: ALINS's short term assets (€6.7M) exceed its long term liabilities (€1.7M).
Debt to Equity History and Analysis
Debt Level: ALINS has more cash than its total debt.
Reducing Debt: ALINS's debt to equity ratio has reduced from 61.6% to 38.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALINS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ALINS has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 68.6% each year.
What is Intrasense current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALINS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALINS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALINS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALINS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALINS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Nicolas Reymond (39 yo)
Mr. Nicolas Reymond has been Chief Executive Officer and Director of Intrasense Société anonyme since February 8, 2018 and August 20, 2018 respectively. Mr. Reymond was a Director of Business Development a...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Nicolas's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Insufficient data to compare Nicolas's compensation with company performance.
Experienced Board: ALINS's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.
Intrasense SA's employee growth, exchange listings and data sources
- Name: Intrasense SA
- Ticker: ALINS
- Exchange: ENXTPA
- Founded: 2004
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: €11.782m
- Shares outstanding: 31.29m
- Website: https://www.intrasense.fr
Number of Employees
- Intrasense SA
- 1231, avenue du Mondial 98
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.